CPNP 2022 Annual Meeting Poster Abstracts

Brittany Weger, PharmD Candidate; Ali Goforth, PharmD Candidate; Alexandra Cunha, PharmD Candidate; Shaina Schwartz, PharmD, BCPP; Julie Cooper, PharmD, BCPS, BCCPHigh Point University, High Point, NCType: Original Research. Background: Individuals with depression are at an increased risk of cardiovascular disease, which may be further complicated by antidepressant-associated QTc prolongation and Torsades de Pointe (TdP). Currently, there is no consensus guidance on QTc calculation, risk assessment, or post-incident management for such cases. Objectives: This review investigates documented cases of antidepressant-associated QTc prolongation and TdP to understand clinical decision-making in these patients. Methods: A structured literature search was conducted to identify case reports describing QTc prolongation or TdP in individuals taking an antidepressant. Reports published between January 2000 and March 2021 were eligible for inclusion. Articles describing patients with antidepressant overdose or omitting a diagnosis of depression, baseline QTc measurement, or maximum QTc measurement were excluded except in the event of sudden cardiac death outside the hospital setting. Bazett, Fridericia, Framingham, and Hodges formulas were used to calculate QTc. Mayo, Tisdale, and RISQ-PATH tools were used to calculate risk scores. Results: A total of 11 case reports met criteria for inclusion. The average patient was a 53.5-year-old female taking an SSRI with baseline and maximum QTc measurements of 420 msec and 535 msec, respectively. Four patients experienced TdP. The three risk scoring tools agreed in 4/11 (36%) cases. For the remaining 7/11 (64%) cases the Tisdale and RISQ-PATH scores identified risk as “low” whereas the Mayo score identified risk as “high”. Only one case specified the QT correction formula utilized. The most common intervention was to stop the antidepressant (45%, 5/11). Conclusions: Available case reports demonstrate a lack of consistency regarding QT correction formula used, risk evaluation techniques, and clinical management strategies. The Mayo risk scoring tool was the most conservative while Tisdale was the least conservative. Future research in this area can seek to develop a standardized approach for antidepressant-associated QTc prolongation in patients.Casey M. Tiefenthaler, PharmD1; Kelly C. Lee, PharmD, MAS, APh, FCCP, BCPP1,21 UC San Diego Health, San Diego, CA; 2 UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CAType: Original Research. Purpose: Transgender adults are highly stigmatized members of society. Consequently, they are significantly more likely to be diagnosed with mood or anxiety-related disorders compared to cisgender individuals. Research efforts directed towards reducing adverse mental health outcomes are warranted. The purpose of this study was to investigate antidepressant prescribing patterns between gender identities and age groups. Methods: In this cross-sectional study, antidepressant prescribing data were collected from adults diagnosed with gender dysphoria (GD) during a 17-year timeframe between January 1, 2005 and October 31, 2021. Eligible patients had a concomitant diagnosis for mood or anxiety-related disorder at the time of their GD diagnosis. Patients with bipolar or obsessive-compulsive disorder were excluded. The primary outcome was to compare classes of antidepressants and number of prescriptions at the time of GD diagnosis between transgender females (MtF), transgender males (FtM), and non-binary (NB) individuals. Secondary outcomes included age group differences in prescribing patterns and gender identity differences in prevalence of comorbid psychiatric illnesses. Results: Of 131 patients who met inclusion criteria, 43% (n = 56) were identified as MtF, 41% (n = 54) as FtM, and 16% (n = 21) as NB. The most common concomitant diagnoses were mood disorders (n = 96, 73%) and generalized anxiety disorder (GAD) (n = 67, 51%). Approximately 37% (n = 48) of patients did not have an active antidepressant prescription at the time of GD and mood and/or anxiety disorder diagnosis. There was no significant difference in number of psychotropic prescriptions between gender identities (P = .357) or age group (P = .378). However, MtFs were prescribed bupropion at significantly higher rates than FtM and NB patients (16%, 11%, 0%, P = .046). Moreover, the prevalence of GAD was significantly greater among FtMs (P = .044) and those ≤ 40 years old (P < .001). Conclusions: Although there was no observable difference in the number of antidepressant prescriptions between gender or age groups, a staggering 37% of patients were not prescribed any antidepressants at time of their GD and mood and/or anxiety disorder. This serendipitous finding elucidates a potential gap in mental healthcare treatment among transgender adults. The study presents a potential opportunity for clinicians to address these health disparities faced by the highly marginalized population of transgender individuals.Carolanne Wartman, PharmD1,2; David Butterfield, PharmD1,2; Lindsey Anderson, PharmD1,2; Michael Peters, PharmD1; Andrew Schmelz, PharmD1,3; Todd Walroth, PharmD1,2; Carol Ott, PharmD1,21 Eskenazi Health, Indianapolis, IN; 2 Purdue University, West Lafayette, IN; 3 Butler University, Indianapolis, INType: Innovative Practices. Background: According to the 2015 US Transgender Survey, respondents reported experiencing serious psychological distress and attempting suicide at a rate significantly higher than the general population (39% vs 5% and 40% vs 4.6%, respectively). Identified barriers of care included costs of service, fear of being mistreated, and being refused care entirely. Psychiatric pharmacists provide a unique opportunity to deliver comprehensive care to these stigmatized individuals. To the best of our knowledge, there is no current literature describing the impact of a psychiatric pharmacist in an interdisciplinary gender health program. Description of Innovative Service: The Gender Health Program was established in March 2016 and provides primary and specialized care to transgender and nonbinary patients of all gender identities. A board-certified psychiatric pharmacist joined the team in May 2020 through a collaborative practice agreement. The pharmacist conducts patient interviews, to healthcare and a for patients. mental health and mental health and and to the pharmacist are by the and a and mental health on The pharmacist patients to The clinical psychiatric pharmacist a total of with a total of from May 2020 to 2021. Patients from to years of and anxiety were the diagnosis with patients and respectively). data baseline and The gender population significant psychological distress and in and outside of the healthcare setting. the rate of depression, and mental health psychiatric pharmacists can provide health outcomes to mental health and management for this of the and impact of this provide a to this in their health PharmD, BCPP; Innovative Practices. Background: the and of for disorder prescribing and of the a the mental health had to an number of patients on Psychiatric clinical pharmacist had the the gap an collaborative approach was to In of 2020 they a psychiatric to disorders a of practice with patients were to the they primary management of all mental health and Patients the at least are and prescription are for the patients to are by the in and with an on of to 31, 2021 the for (n = of the patients with of and the remaining or no (n = for were on average compared with an average of all patients for were for an opportunity to and in care as time is time is by the these which to on more patients or those A collaborative approach to management a psychiatric as the primary to care at this time for care be more and a PharmD1,2; PharmD The of 2 Background: disorder may be the of is more treatment and may or A common is a patient with had a to can no to In this there are three and of or mood or of and patient is a female who had of depression in and of in and of included and The patient had psychiatric psychiatric while on and of and did not have and was with and was to our psychiatric with by and at a of a of taking of and on all except and were and respectively. was and of was the patient was for and for an of search was to identify best for management of during literature these and There is not a treatment for in patients on and is This is the of being in these PharmD1,2; PharmD, Psychiatric of Health, 2 of at School of Pharmacy and Pharmaceutical Sciences, 3 of at School of of Original Research. Background: have an between a of and increased risk for disease, is have the potential to or disorders in patients taking can impact the through to the and potential However, is this disorders for patients taking The of this study is to to a higher risk of disorders in an psychiatric Methods: patients at an psychiatric were to were with more or Patients were included they were at the psychiatric on 31, 2021 and were taking at least one had at least one one and and at least one Patients were excluded they had a a with patients were to disorders on and scores a Results: Of the patients included in the study, there were patients with an score greater than and patients with a of than 40 for and for There was no a and to to more disorders in patients taking the of this study, there is no between patients with and increased disorders or scores. of the patients were taking for which have their in those there was not a significant in scores their PharmD, PharmD Candidate; PharmD, BCPS, BCPP; PharmD, BCPP; PharmD, of Health, Original Research. Purpose: is a used to A to reports of QT prolongation and de a in was to our for the management of in the and Patients a in with and at our of consensus regarding which to on and in this patient Methods: A review was conducted of patients years of age who to the from 1, 2020 to 2021 with a psychiatric and or The primary outcome was to the of in on for Secondary outcomes included the for QTc < and/or < depression rate < or rate < Results: A total of patients were included in patients with a of in the group compared to vs respectively). The of and were and respectively. There were more for for compared to (P < .001). This included and for and for Patients for were higher in the group than the group (P < .001). There were no significant differences in Patients in the group further for 2 more patients in the group likely by our practice of with There were no differences in QTc prolongation or adverse PharmD, PharmD, PharmD, Carol Ott, PharmD, BCPP; PharmD, of Pharmacy Purdue of West Lafayette, INType: Original Research. Purpose: This study to understand and their with for disorder current care by and through the of Methods: were with in a or in and in an A was conducted with in the were on their current in their at as as at regarding and current care in those be all were the data was as as with the all of which three were by a to the of was all were was a time to all were Results: had in for a of years and had as a for a of years identified as in current care barriers identified included a lack of treatment at the to or and of society. the in as one for with as or as most were of or not in of and Future There are for to in care In the be conducted with pharmacists and to of those in PharmD PharmD, BCPS, of of 2 of of in Background: health and are as of for Pharmacy and are at increased risk of experiencing mental and distress during their depression, and in higher with generalized anxiety and depression, documented in the is with a lack of and to to of health and and have with healthcare to provide patient Objectives: the of experienced by PharmD and with prevalence and of between PharmD and Methods: be from a being eligible in the PharmD or a in and being years Eligible an to in an the a the and be outcomes of among respondents as average scores and number of respondents of by the and be to identify the between score and gender and among no in of and gender or to had significantly scores on the score P = an and score were with higher scores = and P < .001). is among PharmD Kelly PharmD, School of 2 in Original Research. and Purpose: The reported a in overdose from between 2020 and 2021 in the Approximately in used to can be a and overdose This study and of and to as a of to Methods: in or treatment for a disorder were from a mental health in the US to a were from research conducted at School of criteria included age to years of age with in the A was by a and was from and for Results: the during the of 2021. Of agreed in more than a to risk for to be to there is in their they in their to Conclusions: respondents who were for of to for who are at greater risk for overdose and likely the most from increased and of healthcare to and overdose to as is to the in overdose in the PharmD PharmD Lindsey PharmD1; M. The of at 2 Research NCType: Original Research. Background: in have compared to US of the of a However, from 2020 to overdose to increased in by is the of in and such research to The purpose of this was to understand the impact of increased on the in Methods: patients at in were to in an their were to they met inclusion criteria, which or in the was collected from 2021 to 2021 from a to and all a were a and approach to identify by Results: identified as female and nonbinary with a age of A identified as and were or in by included to of and in their and to respondents reported being to identify through of or by experiencing increased Conclusions: the of in this who in increased to This for health to for who and and may be in this patient PharmD1; PharmD1; PharmD1; 2 Research Original Research. Background: was for the treatment of adults with from to the differences in and of this of a study and of and Methods: and an and patients of or were to of or during a Patients 3 between active to Results: In the adverse were reported in patients and with most common and respectively). and in of patients in treatment groups. of the were reported as in treatment or scores for from baseline to for in to to Of the active the 2 of were were to increased during in an adverse was to Conclusions: the of a study, with to and to were to in were reported as in treatment or PharmD PharmD Kelly PharmD, 2 Health Original Research. Purpose: the treatment disorder of treatment is The of this study is to prescribing patterns at a healthcare Methods: was to The for this as a practice for a psychiatric pharmacist primary care and prescribing data 2020 to patient and for depression, and disorders were from the health Psychiatric prescribing patterns were further on diagnoses and of vs Results: this patients treatment a had a diagnosis of and disorder were the most common psychiatric this prescribed psychiatric and prescribed psychiatric of the prescribed and of the prescribed with used most antidepressants and for and for with prescribed most by and were the most common and prescribed at for and for with prescribed most was the most common for for and for Conclusions: lack consistency for they all SSRI The of this study are likely the healthcare of this in are to more common while patients with more In this prescribing more current treatment This study the to the of by Andrew C. M. 2 School of Indianapolis, INType: Original Research. Background: is an with no in 3 as a potential treatment for patients with In a 2 study of in with was with significantly greater in and total score at compared with as as on This current provides to time of and and Methods: included of total score of and between baseline and study to for was The of and patients at and was of with Results: A total of patients in the group and patients in the group were included in the rates with from for a to for a rates with were significantly higher than in the with from 3 to 11 was with a higher rate to as as 2 for and 40% and for the of the significant differences by 2 which through Conclusions: rates on total score compared with at further of the primary and was as as 2 to vs in all PharmD, C. PharmD, of School of 2 of 3 of School of of NCType: Original Research. is a area of literature of is This study to the of to three mental and and and identify with these in an to a more of and risk in Methods: was to from The was from the Health Health Health and and a were compared and was used for Results: = from to the rate For of reported < and reported to For mental of for depression and for of were at risk for and were at risk for on and were with for anxiety and (P = and P = while was with (P < and was with for depression (P = This study are at risk for lack of and depression or or In were to be with these and by of PharmD, Health Original Research. Background: are the group in the during a a to patients have taking a to for who to a the be This study on the of and Objectives: To the of in female of of and To provide and as Methods: A was for female the age of years with active or prescriptions a of the Health the patients were for of these were for documented of to or were excluded from the were and Results: patient were no of age were prescribed at the The number of female in group were as on on and on A total of were excluded and of the included were to be and The of reported being of the of their were were for the of the of were documented in the A total of were The not taking were to and of the Conclusions: this study there is a gap in which may be with of of and of PharmD, BCPP; BCPS, Health Indianapolis, INType: Original Research. Background: are to to to is used to and of a is to may on the of the patient or of This may in increased risk for and Objectives: The of this study is to the of with this study to identify in care with and can current prescribing Methods: This review patients who were on a while to the psychiatric from January 1, 2016 to 31, were Secondary outcomes to of and for of was for and for Results: A total of patients were 40 had and had The most common was = and was the most common used = Patients were to in the = and group = of a in was in the group = and group = for of to no and There were no significant differences in outcomes to (P = of (P = and for (P = and Future This study in our of care and are to patients. This provides a area of care pharmacists may be in the patient from an to an PharmD, BCPP; PharmD, Health Original Research. Purpose: in to of patients and of patients. are for treatment and have with hospital and This study patterns of for the treatment of and Methods: A identified patients from with and a diagnosis of mental or between January 1, and 31, the health care Patients were excluded they were to or a psychiatric care an had an on their to or an prescribed by a patients were for for to or and of the Results: the of patients who were (n = and (n = The documented for included (n = (n = mental (n = and (n = was with of increased and to were of the may have were psychiatric (n = of the (n = or to the (n = In groups, was the most prescribed with (n = as the most common There were no significant differences in rates between groups. This study is to the and to a However, can address our health a rate of of and increased with identified our current tools are highly of a may and for Lindsey PharmD1; Andrew M. PharmD, Kelly PharmD, PharmD, BCPS, The of at 2 The University, 3 of the The of Health San Original Research. Background: with disorder be to and in a to risk for of and This study was a in highly and in of and was Methods: A of in (n = and (n = were from 1, 2021 to 2021. a standardized to of and outcomes included of a of and a of and by Secondary outcomes included to and timeframe to were excluded three refused to or were not a Results: were excluded and were in an from in and in were included in the had a of and 131 had a of had greater compared to vs P < while had greater vs P = were significantly likely to have than vs P = and vs P < .001). Of with to with a time of 3 Conclusions: in these are to and with greater in research is to identify and Schwartz, PharmD, High Point University, High Point, 2 Health Health NCType: Original Research. Purpose: as are used in patients. a significant risk of and be used This purpose of this study was to disease, and with the of in the in to understand current prescribing patterns and for Methods: A review of was conducted at a health in the eligible for inclusion were years of age with at least one between January 1, and 31, was used to for between patient health and of adverse Results: The study population = those with and psychiatric and the number of for patient was The of health adverse and were with significantly greater total and prescription of a were greater in and while was more likely in those with a disorder or adverse were significantly with cardiovascular and disorder and Future on the of this study, disease, and are to the of in the hospital setting. is to further these in to the of prescribing and identify for PharmD1,2; PharmD, BCPS, Health 2 of at of Original Research. Purpose: Patients with are at risk for and their risk of 2 patients with be for at of a and In our a clinical to This tool and not This study to in is a for Methods: A identified with a mental health diagnosis on between January 1, 2015 and 31, were for years to in The primary outcome of this study was to compare rate of at for patients with and was as baseline and 3 to Secondary outcomes rate of at of and criteria included baseline or at the time of data Results: patients were with and of at were not significantly between vs no vs P = or at vs P = of and were between the groups. rates of were between risk risk for and Future with of a was not with outcomes for for patients on are to PharmD, Original Research. Background: In the of pharmacists in the hospital from to in the psychiatric pharmacists have of and outcomes in a by pharmacists to differences in hospital and of Objectives: The of this study was to compare psychiatric in the The of on of common and clinical Methods: A of psychiatric was conducted from 1, 2021 to 31, 2021. Pharmacy was from hospital or hospital The included a total of general and clinical were collected from an pharmacist or at the time of the data were Results: of the were a Of and had clinical clinical included management team patient and clinical were by most This be to differences in hospital and to of this study to pharmacist the most the may not of the research more and a more to of pharmacist intervention rates of or collaborative practice and rates of Lindsey PharmD, School of 2 of Pharmacy School of 3 of School of School of Original Research. Purpose: and overdose to be health in the on healthcare during the are the purpose of this study was to understand the general regarding overdose management and Methods: This cross-sectional study a of from a the general of and was to US adults and to an were from were = = and in an overdose regarding in an overdose and to in an overdose were with 2021. Results: Approximately of respondents were female and with age of years = in an overdose to be with of respondents or they be to with an overdose and they to to who However, regarding in an overdose were and to was primary included who and in an overdose In of they to be to in an overdose and reported they was to the of an overdose Conclusions: The US general is to in overdose is to and these may overdose PharmD, BCPS, PharmD, Kelly Lee, PharmD, MAS, APh, PharmD, BCPS, 2 School of 3 of Psychiatric Skaggs School of Pharmacy and Pharmaceutical Sciences, of Diego, San Diego, CA; Health Indianapolis, INType: Original Research. Background: A identified significant of practice among psychiatric pharmacists In to this this to consensus and develop practice for psychiatric pharmacists care in an setting. of these a best practice for care by Objectives: The of this was to develop for a best practice for psychiatric pharmacists patient care the setting. Methods: from were a and The an to a to review data and develop a of the for or a to review and a of to the The of the from 2020 to 2021. Results: from such as and/or and years of practice are for The in the were in The respondents of this (n = were pharmacists for an average of years = and had as psychiatric pharmacists for an average of years = more than of the respondents reported in the and were For of the at least of respondents agreed or agreed with and Future the of on the practice they be used as the for the Psychiatric in this guidance and for evaluation of these in be PharmD Candidate; PharmD, School of Original Research. Background: Patients seek for such as depression, and in a as an in of and in a potential risk is an of and is by this Objectives: The of this study were to the to which the in of and to have in this Methods: and one prescription were used in the at a of was with the of from the of the was conducted in no of and were of at The of was by the in of

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.